Caelum Biosciences, Inc. — Form D/A
Caelum Biosciences, Inc. of NEW YORK, NY, a company, filed a Form D amendment with the SEC on 2017-09-14. The offering totals $10.0M, of which $7.8M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2017-09-14
- Form: D/A
- Accession: 0001714429-17-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $10.0M
- Amount sold: $7.8M
- Remaining: $2.2M
- Investors: 137
- Date of first sale: 2017-08-31
- Security types: debt
- Revenue range: Decline to Disclose
- SEC file number: 021-292630
Issuer
- Name: Caelum Biosciences, Inc.
- CIK: 0001714429
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2015
- Address: 2 GANSEVOORT STREET, NEW YORK, NY, 10014
- Phone: 781-652-4500
Officers, directors & promoters (9)
| Name | Role | Location |
|---|
| Michael Spector | Director | Redwood City, CA |
| Michael Spector | Executive Officer | Redwood City, CA |
| Martin W Goldman | Director | New York, NY |
| Kenneth W Cappell | Director | New Yor, NY |
| William W Natbony | Director | New York, NY |
| Jeffrey S Paley | Director | New York, NY |
| David W Horin | Executive Officer | New York, NY |
| Michael S Weiss | Director | New York, NY |
| Lindsay A Rosenwald | Director | New York, NY |
Other filings by this issuer (2)
More